Patent ID: 11919898
Assignee: SHENZHEN LINGFANG BIOTECH CO., LTD.
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 17:
18. A method of preparing a medicine for treating FGFR and c-Met related diseases, comprising:
mixing a crystal form G of a compound of Formula (III) or a crystal form J of a compound of Formula (IV), the crystal form A according to claim 1, or a crystal form N of a compound of Formula (I) with one or more pharmaceutically acceptable excipients;
wherein the crystal form G of the compound of Formula (III) has an X-ray powder diffraction pattern with characteristic diffraction peaks at 2θ of 6.86°±0.20°, 7.53°±0.20°, and 15.46°±0.20°, the crystal form J of the compound of Formula (IV) has an X-ray powder diffraction pattern with characteristic diffraction peaks at 2θ of 4.59°±0.20°, 7.02°±0.20°, and 18.05°±0.20°, the crystal form N of the compound of Formula (I) has an X-ray powder diffraction pattern with characteristic diffraction peaks at 2θ of 12.64°±0.20°, 17.10°±0.20°, and 20.92°±0.20°;, wherein the FGFR and c-Met related diseases comprise liver cancer, bladdercancer, lung cancer, breast cancer, endometrial cancer, glioma, prostate cancer, gastriccancer, non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, hypopharyngeal cancer, and ovarian cancer.